Literature DB >> 10816217

Treatment of lymphangiomas of the head and neck in children by intralesional injection of OK-432 (Picibanil).

C Brewis1, J P Pracy, D M Albert.   

Abstract

The treatments previously used for lymphangiomas of the head and neck in children-surgery and intralesional injection of sclerosants-are associated with significant morbidity. A new treatment-intralesional injection of OK-432-was used for lymphangiomas of the head and neck in 11 children. The results were total shrinkage in two, marked shrinkage in two, slight shrinkage in five and no response in two. The results were not affected by previous surgery nor by whether aspiration prior to injection was possible. There were no recurrences in those children in whom shrinkage occurred and no child had subsequent surgery following injection. The results of this series support those of previous series showing that OK-432 injection is an effective and safe treatment for lymphangiomas of the head and neck in children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816217     DOI: 10.1046/j.1365-2273.2000.00338.x

Source DB:  PubMed          Journal:  Clin Otolaryngol Allied Sci        ISSN: 0307-7772


  7 in total

1.  OK-432 sclerotherapy of plunging ranula in 21 patients: it can be a substitute for surgery.

Authors:  M H Rho; D W Kim; J S Kwon; S W Lee; Y S Sung; Y K Song; M G Kim; S G Kim
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

2.  OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome.

Authors:  Dong Wook Kim
Journal:  Pediatr Radiol       Date:  2014-02-26

3.  [Sclerotherapy with OK-432 for cystic tumors in the neck region].

Authors:  M Bloching; G Götze; M Passmann; K Neumann
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

4.  [Lymphatic malformations in the head and neck region. Clinical aspects and therapeutic options].

Authors:  B Eivazi; J A Werner
Journal:  HNO       Date:  2014-01       Impact factor: 1.284

5.  Efficacy of OK-432 sclerotherapy in treatment of lymphatic malformations: long-term follow-up results.

Authors:  Annamaria Weitz-Tuoretmaa; Riitta Rautio; Jan Valkila; Harri Keski-Säntti; Leo Keski-Nisula; Jussi Laranne
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-07       Impact factor: 2.503

Review 6.  Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma.

Authors:  Darrin V Bann; Daniel G Deschler; Neerav Goyal
Journal:  Cancers (Basel)       Date:  2016-09-22       Impact factor: 6.639

7.  Treatment of giant cervico-mediastinal lymphatic malformations: a case series.

Authors:  So-Hyun Nam; Kyoung-Ah Kwon
Journal:  J Med Case Rep       Date:  2018-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.